A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
In this phase 1/2 study, carfilzomib was added to high-dose melphalan conditioning prior to autologous st...
Read moreIn this phase 1/2 study, carfilzomib was added to high-dose melphalan conditioning prior to autologous st...
Read moreResearchers have long known that moderate exercise has a beneficial impact on the body’s response to infl...
Read moreMultiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is the second-mos...
Read moreSecondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum...
Read moreMultiple myeloma usually affects older adults. However, younger patients constitute a significant subset...
Read moreDuring Myeloma and Amyloidosis Awareness Month, the Canadian government took an important step towards im...
Read moreJoin our community and sign up for our newsletter.